INCYTE

The latest PrZYNYZ® tools all in one place

ZYNYZ® (retifanlimab for injection), as monotherapy, is indicated for the first-line treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC) not amenable to curative surgery or radiation therapy.1

The resources below are designed to help your patients by providing key information about ZYNYZ®.
View, download, or print the tools for future use.

Please email IncyteCanadaInquiry@incyte.com to request copies of the tools.

For Your Patients

ZYNYZ® Patient
Brochure

View
Download
Print

ZYNYZ® Risk Management
Plan (RMP) Card

View
Download
Print

Safety information1

Clinical use:

Marketing authorization was based on tumor response and durability of response. An improvement in survival or disease-related symptoms has not yet been established. 

Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 

Contraindications:

  • ZYNYZ® is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. 

Relevant warnings and precautions: 

  • Exercise caution when driving or operating a vehicle or potentially dangerous machinery
  • Immune-mediated adverse reactions, which may be severe or fatal, can occur in patients treated with antibodies blocking the programmed death receptor 1/programmed death ligand 1 (PD-1/PD-L1) pathway, including ZYNYZ®; these reactions usually occur during treatment with PD-1/PD-L1 blocking antibodies, but symptoms can also manifest after treatment discontinuation
  • Immune-mediated adverse reactions: pneumonitis, immune-mediated colitis, immune-mediated nephritis, immune-mediated hepatitis, immune-mediated skin reactions (including toxic epidermal necrolysis), immune-mediated endocrinopathies, immune-mediated hypothyroidism and hyperthyroidism (including thyroiditis), immune-mediated hypophysitis, immune-mediated adrenal insufficiency, immune-mediated type 1 diabetes mellitus, have been reported in patients receiving ZYNYZ®
  • Solid organ transplant rejection has been reported in the post-marketing setting in patients treated with PD-1 inhibitors; treatment with ZYNYZ® may increase the risk of rejection in solid organ transplant recipients
  • Fatal and other serious complications can occur in patients who receive allogeneic hematopoietic stem cell transplantation (HSCT) before or after being treated with a PD-1/PD-L1-blocking antibody
  • Transplant-related complications include hyperacute graft-versus-host disease (GvHD), acute GvHD, chronic GvHD, hepatic veno-occlusive disease after reduced intensity conditioning and steroid-requiring febrile syndrome (without an identified infectious cause)
  • As with any therapeutic protein, ZYNYZ® can cause infusion-related reactions, some of which may be severe
  • Based on its mechanism of action, ZYNYZ® can cause fetal harm when administered to a pregnant woman; there are no available data on the use of ZYNYZ® in pregnant women
  • ZYNYZ® has the potential to be transmitted from the mother to the developing fetus
  • ZYNYZ® is not recommended during pregnancy and in women of childbearing potential not using effective contraception unless the clinical benefit outweighs the potential risk
  • Women of childbearing potential should use effective contraception during treatment with ZYNYZ® and for at least 4 months after the last dose
  • Women should be advised not to breastfeed during treatment and for at least 4 months after the last dose of ZYNYZ®; a risk to the breastfeeding newborns/infants cannot be excluded

For more information:

Please consult the Product Monograph here for important information relating to monitoring and laboratory tests, adverse reactions, drug interactions, and dosing information which have not been discussed in this piece. The Product Monograph is also available by calling 1-833-309-2759 or contacting medinfocanada@incyte.com. 

Reference: 1. ZYNYZ® Product Monograph. Incyte Corporation. February 6, 2025.   

ZYNYZ and the ZYNYZ logo are registered trademarks of Incyte.
Incyte and the Incyte logo are registered trademarks of Incyte.
INCYTE SOLUTIONS and INCYTE SOLUTIONS logo are trademarks of Incyte.
All other trademarks are the property of their respective owners.
© 2022–2026, Incyte. All rights reserved.

Menu
INCYTE
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.